Table 3.
Published series about SBRT for sarcoma lung metastases
| Authors | Year | No. of patients | No. of lesions | Total dose/ No. of fractions | Median F/U (months) |
2 years L.C (%) |
2 years O.S (%) |
Toxicity Gr ≥ 3 (%) |
|---|---|---|---|---|---|---|---|---|
| Dhakal et al. (preferred)[55] | 2012 | 14 | 74 | 50 Gy/5 fr | 11 | 88 | 69 | None |
| Frakulli et al.[56]† | 2015 | 24 | 68 | 30–60 Gy/3–8 fr | 17 | 86 | 66 | None |
| Navarria et al. [57] | 2015 | 28 | 51 | 48 Gy/4 fr (preferred) | 21 | 96 | 56 | None |
| Soyfer et al. [58] | 2017 | 22 | 53 | 60 Gy/3 fr | 95 | 100* | 50* | n.r |
| Lindsay et al.[45]† | 2018 | 44 | 117 | 50 Gy/10 fr (preferred) | 14 | 95‡ | 82 | 2 |
| Baumann et al.[59]† | 2020 | 56 | 44 | 50 Gy/4–5 fr | 16 | 90 | 46 | None |
*5 year rate
†These studies included patients with both soft tissue and bone sarcomas
‡Local pulmonary control rate